Carcinoma basocelular periocular tratado con una mezcla de interferones en la atención primaria
Keywords:
basal cell carcinoma and therapy, non melanoma skin cancer, IFN alpha-2, HeberFERON, interferonsAbstract
Introduction: Basal cell carcinoma is the malignant tumor with the highest incidence among the eyelid’s neoplasms. It has a high potential for local destruction. Surgical treatment, of choice among therapeutic modalities, can compromise aesthetics and eye function.
Objective: To describe the results of the application of HeberFERON in patients diagnosed with periocular basal cell carcinoma.
Methods: An observational, descriptive, and prospective study was carried out. 15 patients treated in the skin tumor clinic at the Dr. Carlos J. Finlay polyclinic in the Colon, Matanzas, were included. They had a diagnosis by histopathology of basal cell carcinoma, with periocular location, and with a size where surgery was unsightly. The investigation was conducted between January 2017 and December 2023. The patients were evaluated at weeks 0, 4,8, and 16 after treatment. A dose of 10,5 million international units of HeberFERON was administered three times per week perilesional and intradermal to complete nine doses. The variables were: age, sex, skin phototype, location, tumor type, histological subtype, clinical stage, time of evolution, clinical and dermatoscopic response to treatment
Results: Male sex, skin phototype II, lower eyelid location, solid histologic subtype, primary tumors, and stage IA, were more frequent. Complete response was achieved in 46.7% and partial response in 20%. The coincidence of complete clinical and dermatoscopic responses occurred in 71.2%.
Conclusions: HeberFERON was a therapeutic alternative for use in basal cell carcinoma with palpebral location.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Meilyn Fernández Martori, Yamirka Irina Rojas Pérez, Samia Hernández Drake, Silvio Faustino Faustino Soler Cárdenas, Jorge Bacallao Gallestey
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
